Cargando…
Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder
BACKGROUND: Social anxiety disorder (SAD) is associated with substantial reduction in health-related quality of life (HRQoL). Escitalopram has proven efficacy in the short-term treatment of SAD and prevention of relapse. OBJECTIVES: To determine whether the clinical effects of treatment translated i...
Autores principales: | François, C, Montgomery, S A, Despiegel, N, Aballéa, S, Roïz, J, Auquier, P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704928/ https://www.ncbi.nlm.nih.gov/pubmed/18759783 http://dx.doi.org/10.1111/j.1742-1241.2008.01879.x |
Ejemplares similares
-
The Prevalence of Generalised Anxiety Disorder Among Prisoners of the Penitentiary Institution in North-Eastern Poland
por: Stawinska-Witoszynska, Barbara, et al.
Publicado: (2021) -
Quality of life is predictive of relapse in schizophrenia
por: Boyer, Laurent, et al.
Publicado: (2013) -
Resistant social anxiety disorder response to Escitalopram
por: Pallanti, Stefano, et al.
Publicado: (2006) -
Metoprolol, N-Acetylcysteine, and Escitalopram Prevents Chronic Unpredictable Mild Stress-Induced Depression by Inhibition of Endoplasmic Reticulum Stress
por: Yang, Lixia, et al.
Publicado: (2018) -
Colchicine-Resistant Familial Mediterranean Fever With Depressive State Successfully Treated With Escitalopram
por: Toshida, Masamitsu, et al.
Publicado: (2021)